• 1. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 2. Aggregation-induced emission of luminol: a novel strategy for fluorescence ratiometric detection of ALP and As(v) with high sensitivity and selectivity?
  Yuan-Jun Tong,Lu-Dan Yu,Lu-Lu Wu,Shu-Ping Cao,Ru-Ping Liang,Li Zhang,Xing-Hua Xia,Jian-Ding Qiu Chem. Commun., 2018,54, 7487-7490
• 3. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 4. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 5. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554

Recent Advances in the Study of 5-methyl-1H-indazol-3-ylamine (CAS: 88805-94-1) in Chemical Biology and Pharmaceutical Research

The compound 5-methyl-1H-indazol-3-ylamine (CAS: 88805-94-1) has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This heterocyclic amine, characterized by its indazole core structure, has been explored for its role in modulating various biological pathways, particularly in the context of kinase inhibition and cancer therapy. Recent studies have highlighted its utility as a key intermediate in the synthesis of novel therapeutic agents, underscoring its importance in drug discovery and development.

One of the most notable advancements in the study of 5-methyl-1H-indazol-3-ylamine is its application in the design of kinase inhibitors. Kinases play a critical role in cellular signaling and are often dysregulated in diseases such as cancer. Researchers have utilized 5-methyl-1H-indazol-3-ylamine as a scaffold to develop selective inhibitors targeting specific kinases, including those involved in tumor proliferation and metastasis. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's efficacy in inhibiting the activity of c-Met kinase, a key driver in hepatocellular carcinoma. The study reported that derivatives of 5-methyl-1H-indazol-3-ylamine exhibited potent inhibitory activity with improved selectivity profiles compared to existing therapeutics.

In addition to its role in kinase inhibition, 5-methyl-1H-indazol-3-ylamine has been investigated for its potential in addressing antimicrobial resistance. A recent study in Bioorganic & Medicinal Chemistry Letters explored the compound's derivatives as novel antibacterial agents. The researchers synthesized a series of analogs and evaluated their activity against multidrug-resistant bacterial strains. The results indicated that certain derivatives exhibited promising antibacterial efficacy, particularly against Gram-positive pathogens such as Staphylococcus aureus. This finding opens new avenues for the development of next-generation antibiotics to combat resistant infections.

The synthetic versatility of 5-methyl-1H-indazol-3-ylamine has also been a focal point of recent research. Advances in synthetic methodologies have enabled the efficient production of this compound and its derivatives, facilitating further exploration of its pharmacological properties. A 2022 publication in Organic Process Research & Development detailed a scalable and cost-effective synthesis route for 5-methyl-1H-indazol-3-ylamine, emphasizing its potential for industrial-scale production. This development is particularly significant for pharmaceutical companies aiming to incorporate the compound into large-scale drug manufacturing processes.

Despite these promising advancements, challenges remain in the clinical translation of 5-methyl-1H-indazol-3-ylamine-based therapeutics. Issues such as bioavailability, metabolic stability, and off-target effects need to be addressed to ensure the compound's suitability for human use. Ongoing research is focused on optimizing the pharmacokinetic and pharmacodynamic properties of 5-methyl-1H-indazol-3-ylamine derivatives, with several preclinical studies currently underway. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the transition of these compounds from the lab to the clinic.

In conclusion, 5-methyl-1H-indazol-3-ylamine (CAS: 88805-94-1) represents a versatile and promising scaffold in chemical biology and pharmaceutical research. Its applications in kinase inhibition, antimicrobial therapy, and drug synthesis highlight its broad potential. Continued research and development efforts are essential to fully realize the therapeutic benefits of this compound and its derivatives. As the field progresses, 5-methyl-1H-indazol-3-ylamine is likely to play an increasingly important role in addressing unmet medical needs and advancing precision medicine.

• 874-05-5(1H-Indazol-3-amine)
• 830321-62-5(1H-Indazol-3-amine, 5,7-dimethyl-)
• 54107-84-5(2H-Indazol-3-amine)
• 368426-75-9(6-(aminomethyl)-1H-indazol-3-amine)
• 20925-62-6(3-Amino-1H-indazole-5-carbonitrile)
• 267413-32-1(3-Amino-1H-indazole-6-carbonitrile)
• 1000343-59-8(3-Amino-7-methyl (1H)indazole)
• 866187-25-9(1H-Indazol-3-amine hydrochloride)
• 871709-90-9(1H-Indazole-3,6-diamine)
• 835616-39-2(6-Methyl-1H-indazol-3-ylamine)